Phase II study of goserelin for patients with postmenopausal metastatic breast cancer.
OBJECTIVE
To determine the response rate of postmenopausal breast cancer patients to the gonadotropin-releasing hormone (GN-RH) agonist, Zoladex (goserelin; ICI Pharma, Wilmington, DE).


METHODS
A multi-institutional single-agent trial in postmenopausal patients was conducted. Serum levels of follicle-stimulating hormone (FSH), testosterone, and estradiol were requested before and after Zoladex treatment.


RESULTS
For estrogen receptor-positive (ER+) patients, the response rate was 11%, with one complete response (CR) and three partial responses (PRs) among 36 eligible patients. Responses were of short duration. There were no responses among 16 estrogen receptor-negative (ER-) patients.


CONCLUSIONS
GN-RH agonists have activity in ER+ postmenopausal patients, but response rates are not as high as with other available endocrine therapies and the duration of response is short.
Saphner
T
T
University of Wisconsin Comprehensive Cancer Center, Madison.
Troxel
A B
AB
Tormey
D C
DC
Neuberg
D
D
Robert
N J
NJ
Pandya
K J
KJ
Edmonson
J H
JH
Rosenbluth
R J
RJ
Abeloff
M D
MD
D000368:Aged; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D012739:Gonadal Steroid Hormones / Q000097:blood; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011960:Receptors, Estrogen / Q000378:metabolism; D016019:Survival Analysis; D016896:Treatment Outcome
D012739:Gonadal Steroid Hormones; D011960:Receptors, Estrogen; D017273:Goserelin; D005640:Follicle Stimulating Hormone